Synapse Open Synapse
Sport

‘Bespoke’ mRNA vaccine significantly reduces risk of melanoma recurrence or death, clinical trial shows

The Guardian · · 3 min read

Trial results represent ‘foundational shift’ in approach to cancer, allowing scientists to harness immune system in more personalised way Get our new political email , free app or daily news podcast A personalised mRNA-based melanoma vaccine significantly reduces the risk of cancer recurrence or death within two years, new clinical trial results show.

Same story elsewhere

Latest from The Guardian